Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Changes in the tumour microenvironment after intravenous or intradermal administration of anti-CTLA-4 with anti-PD1 in melanoma
2024-516545-39-01Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipilimumab in melanoma (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: T cell subset frequencies and systemic activation in PBMCs. Planned start Mar 2026; status: authorised.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-516545-39-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516545-39-01.